Weekly injection for obesity without diabetes
Treatments studied
Part of Hormones & metabolism clinical trials.
This trial tests a new once-weekly injection called Ribupatide for weight loss in people with obesity who do not have diabetes. It compares the study drug to an existing medication (semaglutide) and a placebo to see how well it works and if it's safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your body mass index (BMI) must be 35 or higher.
- You must have tried to lose weight through diet or exercise in the last 6 months without success.
- You cannot have diabetes or a history of diabetes.
- Your weight must have stayed stable (not changed more than 5%) in the last 3 months.
- You cannot have started certain weight-affecting medications (like some antidepressants) in the last 3 months.
- You cannot have a personal or family history of certain thyroid cancers or a condition called multiple endocrine neoplasia type 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a once-weekly injection (tirzepatide) versus a placebo to help people who are obese or overweight with related health conditions lose weight. You may qualify if you have tried to lose weight through diet before, but have not been successful.
This study tests a weekly injection called semaglutide to see how well it helps people with obesity lose weight, compared to a similar approved medicine, Wegovy. It may be an option if you have struggled to lose weight in the past.
This study tests a new weekly injection (called NNC0487-0111) against an existing medicine (semaglutide) to see if it helps people with type 2 diabetes lose more weight. Together with standard diabetes care and lifestyle changes, you would receive the study medicine for about a year, and the study team will monitor your health and weight.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This study tests whether a low dose of semaglutide (a once-weekly injection) can help obese adults without diabetes lose weight. Semaglutide works by reducing appetite and helping your body use food differently.
This study tests a once-weekly injection called berobenatide to see if it helps adults with obesity lose weight and improve related health problems like high blood pressure, high cholesterol, or blood sugar issues. It is for people living in Japan.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.